236 related articles for article (PubMed ID: 33850907)
1. Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review.
Conte C; Fagotti A; Avesani G; Trombadori C; Federico A; D'Indinosante M; Giudice MT; Pelligra S; Lodoli C; Marchetti C; Ferrandina G; Scambia G; Gallotta V
Ann Transl Med; 2021 Mar; 9(6):510. PubMed ID: 33850907
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients.
So M; Miyamoto T; Murakami R; Abiko K; Hamanishi J; Baba T; Mandai M
J Gynecol Oncol; 2019 Nov; 30(6):e100. PubMed ID: 31576692
[TBL] [Abstract][Full Text] [Related]
3. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
4. Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer.
Jiang C; Li Z
Front Oncol; 2021; 11():674637. PubMed ID: 34631517
[TBL] [Abstract][Full Text] [Related]
5. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Goldberg RM; Kim SR; Fazelzad R; Li X; Brown TJ; May T
Gynecol Oncol; 2022 Jan; 164(1):212-220. PubMed ID: 34756470
[TBL] [Abstract][Full Text] [Related]
6. The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis.
Ding T; Tang D; Xi M
J Ovarian Res; 2021 Jul; 14(1):93. PubMed ID: 34256813
[TBL] [Abstract][Full Text] [Related]
7. Surgery
Capozzi VA; Rosati A; Turco LC; Sozzi G; Riccò M; Chiofalo B; Vizzielli G
Gland Surg; 2020 Aug; 9(4):1112-1117. PubMed ID: 32953626
[TBL] [Abstract][Full Text] [Related]
8. Comparison of secondary cytoreductive surgery plus chemotherapy with chemotherapy alone for recurrent epithelial ovarian, tubal, or peritoneal carcinoma: A propensity score-matched analysis of 112 consecutive patients.
Takahashi A; Kato K; Matsuura M; Katsuda T; Matoda M; Nomura H; Okamoto S; Kanao H; Kondo E; Omatsu K; Utsugi K; Takeshima N
Medicine (Baltimore); 2017 Sep; 96(37):e8006. PubMed ID: 28906381
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
10. Prognosis Following Surgery for Recurrent Ovarian Cancer and Diagnostic Criteria Predictive of Cytoreduction Success: A Systematic Review and Meta-Analysis.
Gaba F; Blyuss O; Chandrasekaran D; Bizzarri N; Refky B; Barton D; Ind T; Nobbenhuis M; Butler J; Heath O; Jeyarajah A; Brockbank E; Lawrence A; Manchanda R; Dilley J; Phadnis S; On Behalf Of The Go Soar Collaborative
Diagnostics (Basel); 2023 Nov; 13(22):. PubMed ID: 37998621
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis.
Liu Y; Huang Y; Li J; Wan S; Jiang N; Yang J; Chiampanichayakul S; Tima S; Anuchapreeda S; Wu J
Front Pharmacol; 2022; 13():1010626. PubMed ID: 36438821
[No Abstract] [Full Text] [Related]
12. Secondary cytoreduction in ovarian cancer: who really benefits?
Giudice MT; D'Indinosante M; Cappuccio S; Gallotta V; Fagotti A; Scambia G; Petrillo M
Arch Gynecol Obstet; 2018 Nov; 298(5):873-879. PubMed ID: 30255344
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer progressed after prior poly (adenosine diphosphate-ribose) polymerase inhibitors: A retrospective cohort study.
Zhao Y; Yuan H; Chen Y; Yao H; Li N; Wu L; Yuan G
Eur J Surg Oncol; 2024 May; 50(7):108383. PubMed ID: 38704898
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases.
Gallotta V; Conte C; D'Indinosante M; Capoluongo E; Minucci A; De Rose AM; Ardito F; Giuliante F; Di Giorgio A; Zannoni GF; Fagotti A; Margreiter C; Scambia G; Ferrandina G
Eur J Surg Oncol; 2019 Nov; 45(11):2096-2102. PubMed ID: 31227342
[TBL] [Abstract][Full Text] [Related]
15. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
16. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study.
Petrillo M; Zucchetti M; Cianci S; Morosi L; Ronsini C; Colombo A; D'Incalci M; Scambia G; Fagotti A
J Gynecol Oncol; 2019 Jul; 30(4):e59. PubMed ID: 31074245
[TBL] [Abstract][Full Text] [Related]
18. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis.
Petrillo M; Pedone Anchora L; Tortorella L; Fanfani F; Gallotta V; Pacciani M; Scambia G; Fagotti A
Gynecol Oncol; 2014 Aug; 134(2):257-61. PubMed ID: 24910451
[TBL] [Abstract][Full Text] [Related]
19. Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.
Jeong SY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS; Lee YY
J Ovarian Res; 2019 Dec; 13(1):1. PubMed ID: 31892329
[TBL] [Abstract][Full Text] [Related]
20. A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection.
Angioli R; Capriglione S; Aloisi A; Ricciardi R; Scaletta G; Lopez S; Miranda A; Di Pinto A; Terranova C; Plotti F
Ann Surg Oncol; 2015 Dec; 22(13):4217-23. PubMed ID: 25808099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
